References
- Böhme K , LikarR. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic15 , 193–202 (2003).
- Sittl R , GriessingerN, LikarR. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.25 , 150–168 (2003).
- Sorge J , SittlR. Transdermal buprenorphine in chronic pain: results from a Phase III, randomized, double-blind, placebo-controlled multicenter study. Clin. Ther.26 , 1808–1820 (2004).
- Griessinger N , SittlR, LikarR. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr. Med. Res. Opin.21 , 1147–1156 (2005).
- Varrassi G , Müller-SchwefeG, PergolizziJ et al. Pharmacological treatment of chronic pain – the need for CHANGE. Curr. Med. Res. Opin. 26(5) , 1231–1245 (2010).
- Brennan MJ , LiebermanJA 3rd. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr. Med. Res. Opin.25(5) , 1045–1055 (2009).
- Pergolizzi J , AloisiAM, DahanA et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 10(5) , 428–450 (2010).
▪ Website
- Grünenthal GmbH. Transtec 35, 52.5 and 70 micrograms per hour transdermal patch – summary of product characteristics. www.grunenthal.com/cms/cda/_common/inc/display_file.jsp?fileID=9400035